Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TatD DNase domain containing 2 pseudogene 2 (TATDN2P2) is classified as a pseudogene, which means it is a duplicate or partial copy of a protein-coding gene—in this case, related to the TatD DNase domain containing 2 gene—but has been rendered nonfunctional by disabling mutations[1][2][3]. Pseudogenes do not encode functional proteins and are traditionally considered non-functional “junk” DNA; however, emerging research indicates some pseudogenes are transcribed and can regulate their parent genes through functions at the RNA level, such as acting as decoys for microRNAs or generating regulatory non-coding RNAs[1][3]. There is no evidence that TATDN2P2 is independently functional, or that it plays a direct role in disease or is a therapeutic target. Therefore, it is not considered a receptor, enzyme, transporter, or actionable drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TatD DNase domain containing 2 pseudogene 2 (TATDN2P2).